Inventor

CISKE FRED LAWRENCE

US13 patents

⚠️ This page may combine multiple inventors who share the name “CISKE FRED LAWRENCE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CAYMAN CHEMICAL CO INC

11 patents

US9487478B2Nov 8, 2016

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC4 citations82

US9180116B2Nov 10, 2015

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC6 citations82

US9440919B2Sep 13, 2016

Difluorolactam compositions for EP4-mediated osteo related diseases and conditions

CAYMAN CHEMICAL CO INC4 citations81

US9701630B2Jul 11, 2017

Difluorolactam compositions for EP4-mediated osteo related diseases and conditions

CAYMAN CHEMICAL CO INC2 citations70

US11884624B2Jan 30, 2024

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC0 citations61

US11066361B2Jul 20, 2021

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC0 citations61

US10556862B2Feb 11, 2020

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC0 citations49

US9126973B2Sep 8, 2015

Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases

CAYMAN CHEMICAL CO INC0 citations46

US10729810B2Aug 4, 2020

Methods, systems, and compositions for promoting bone growth

CAYMAN CHEMICAL CO INC0 citations39

US9676712B2Jun 13, 2017

Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC0 citations39

US9688627B2Jun 27, 2017

Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

CAYMAN CHEMICAL CO INC0 citations38

ENDRES GREGORY W

1 patent

US8536185B2Sep 17, 2013

Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases

ENDRES GREGORY W2 citations53

BARRETT STEPHEN DOUGLAS

1 patent

US9120820B2Sep 1, 2015

Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins

BARRETT STEPHEN DOUGLAS1 citations32